Capecitabine Induced Hand-Foot Syndrome: A Systematic Review of Case Reports

Aras, Elif; Yucel, Kamer Tecen; Bayraktar-Ekincioglu, Aygin; Güllü, İbrahi̇m

doi:10.5152/clinexphealthsci.2018.1250

Search citation statements

Order By: Relevance

Paper Sections

Select...

Introduction1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2020

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Capecitabine has been approved for the treatment of several kinds of cancers including advanced breast cancer which is unresponsive to anthracycline and paclitaxel-containing regimen [4]. It has also been approved for the treatment of metastatic colorectal cancer as first-line therapy [5]. In 2016 meta-analysis, the effect of capecitabine-based regimen as a first-line therapy was compared to free-capecitabine regimen in advanced-stage breast cancer.…”

Section: Introductionmentioning

confidence: 99%

Hand and Foot Syndrome Associated with Capecitabine

Alsaloumi¹,

Shawagfeh²,

Başgut³

2020

ACO

View full text Add to dashboard Cite

Having cancer impacts the patient both psychologically and physically. However, if cancer is accompanied with HFS, the patient’s condition gets even worse. Capecitabine is a prodrug approved to treat several types of cancer such as breast and colorectal cancer. It is associated with several adverse effects such as hand and foot syndrome (HFS) which mostly affects the palms and legs. The provoked mechanisms of HFS are not clear yet. They require further validation of HFS pathogenesis. Up to now, prevention and treatment of HFS are not clearly solidified. Evidence supports the use of celecoxib, urea-based creams, and vitamin E to reduce the severity and the incidence of HFS. This review aims to provide the gaps and ways to further clinical evaluations.

show abstract

Section: Introductionmentioning

confidence: 99%